Synergistic antitumor interactions between gemcitabine and clofarabine in human pancreatic cancer cell lines

Molecular Medicine Reports

Volumn 5, Issue 3, 2012, Pages 734-738

  Guo, Yingjie ^a   Xu, Xuelian ^a   Qi, Wenxiu ^a   Xie, Chengzhi ^a   Wang, Guan ^a   Zhang, Aijun ^a   Ge, Yubin ^a,b  

^a JILIN UNIVERSITY   (China)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Clofarabine; Gemcitabine; Pancreatic cancer; Synergistic antitumor interaction

Indexed keywords

CLOFARABINE; GEMCITABINE;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG POTENTIATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; NITROBLUE TETRAZOLIUM TEST; PANCREAS CANCER;

ADENINE NUCLEOTIDES; ANTINEOPLASTIC AGENTS; APOPTOSIS; ARABINONUCLEOSIDES; CELL LINE, TUMOR; DEOXYCYTIDINE; DRUG SYNERGISM; HUMANS; PANCREATIC NEOPLASMS; S PHASE CELL CYCLE CHECKPOINTS;

EID: 84863055333     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2011.738     Document Type: Article

References (23)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2008. CA Cancer J Clin 58: 71-96, 2008. (Pubitemid 351521864)
2. Burris HA III, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413, 1997. (Pubitemid 27251144)
3. Kullmann F, Hollerbach S, Dollinger MM, et al: Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: a multicentre phase II study. Br J Cancer 100: 1032-1036, 2009.
4. Li J and Saif MW: Advancements in the management of pancreatic cancer. JOP 10: 109-117, 2009.
5. Mini E, Nobili S, Caciagli B, Landini I and Mazzei T: Cellular pharmacology of gemcitabine. Ann Oncol 17 (Suppl 5): 7-12, 2006.
6. Giovannetti E, Danesi R, Mey V, Nannizzi S, Pasqualetti G and del Tacca M: In vitro studies on gemcitabine combinations with other antiblastics. Ann Oncol 17 (Suppl 5): 17-19, 2006.
7. Damaraju D, Damaraju VL, Brun M, et al: Cytotoxic activities of nucleoside and nucleobase analog drugs in malignant mesothelioma: characterization of a novel nucleobase transport activity. Biochem Pharmacol 75: 1901-1911, 2008.
8. Lech-Maranda E, Korycka A and Robak T: The interaction of gemcitabine and cytarabine on murine leukemias L1210 or P388 and on human normal and leukemic cell growth in vitro. Haematologica 85: 588-594, 2000. (Pubitemid 30450937)
9. Tosi P, Pellacani A, Zinzani PL, Magagnoli M, Visani G and Tura S: In vitro study of the combination gemcitabine + fludarabine on freshly isolated chronic lymphocytic leukemia cells. Haematologica 84: 794-798, 1999. (Pubitemid 29474367)
10. Zhenchuk A, Lotfi K, Juliusson G and Albertioni F: Mechanisms of anti-cancer action and pharmacology of clofarabine. Biochem Pharmacol 78: 1351-1359, 2009.
11. Bonate PL, Arthaud L, Cantrell WR Jr, Stephenson K, Secrist JA III and Weitman S: Discovery and development of clofarabine: a nucleoside analogue for treating cancer. Nat Rev Drug Discov 5: 855-863, 2006. (Pubitemid 44480539)
12. Faderl S, Gandhi V, Keating MJ, Jeha S, Plunkett W and Kantarjian HM: The role of clofarabine in hematologic and solid malignancies - development of a next-generation nucleoside analog. Cancer 103: 1985-1995, 2005. (Pubitemid 40605104)
13. Kantarjian HM, Jeha S, Gandhi V, Wess M and Faderl S: Clofarabine: past, present, and future. Leuk Lymphoma 48: 1922-1930, 2007.
14. Waud WR, Schmid SM, Montgomery JA and Secrist JA III: Preclinical antitumor activity of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) adenine (Cl-F-ara-A). Nucleosides Nucleotides Nucleic Acids 19: 447-460, 2000. (Pubitemid 30230053)
15. Taub JW, Huang X, Matherly LH, et al: Expression of chromosome 21-localized genes in acute myeloid leukemia: differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin. Blood 94: 1393-1400, 1999. (Pubitemid 29380420)
16. Xie C, Edwards H, Xu X, et al: Mechanisms of synergistic antileukemic interactions between valproic acid and cytarabine in pediatric acute myeloid leukemia. Clin Cancer Res 16: 5499-5510, 2010.
17. Chou TC: Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58: 621-681, 2006.
18. Tallarida RJ: Drug synergism: its detection and applications. J Pharmacol Exp Ther 298: 865-872, 2001.
19. Ten Cate B, Samplonius DF, Bijma T, de Leij LF, Helfrich W and Bremer E: The histone deacetylase inhibitor valproic acid potently augments gemtuzumab ozogamicin-induced apoptosis in acute myeloid leukemic cells. Leukemia 21: 248-252, 2007. (Pubitemid 46158116)
20. Chow KU, Ries J, Weidmann E, et al: Induction of apoptosis using 2′,2′ difluorodeoxycytidine (gemcitabine) in combination with antimetabolites or anthracyclines on malignant lymphatic and myeloid cells. Antagonism or synergism depends on incubation schedule and origin of neoplastic cells. Ann Hematol 79: 485-492, 2000.
21. Frewin RJ and Johnson SA: The role of purine analogue combinations in the management of acute leukemias. Hematol Oncol 19: 151-157, 2001. (Pubitemid 34072435)
22. Giovannetti E, Mey V, Danesi R, Mosca I and del Tacca M: Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines. Clin Cancer Res 10: 2936-2943, 2004. (Pubitemid 38619668)
23. Giovannetti E, Mey V, Nannizzi S, et al: Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol 68: 110-118, 2005. (Pubitemid 41002949)